Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 5;30(5):taad106.
doi: 10.1093/jtm/taad106.

Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections

Hiam Chemaitelly  1 , Houssein H Ayoub  2 , Sawsan AlMukdad  1 , Jeremy S Faust  3 , Patrick Tang  4 , Peter Coyle  5 , Hadi M Yassine  2 , Asmaa A Al Thani  2 , Hebah A Al-Khatib  2 , Mohammad R Hasan  4 , Zaina Al-Kanaani  5 , Einas Al-Kuwari  5 , Andrew Jeremijenko  5 , Anvar H Kaleeckal  5 , Ali N Latif  5 , Riyazuddin M Shaik  5 , Hanan F Abdul-Rahim  2 , Gheyath K Nasrallah  2 , Mohamed G Al-Kuwari  6 , Adeel A Butt  5 , Hamad E Al-Romaihi  7 , Mohamed H Al-Thani  7 , Abdullatif Al-Khal  5 , Roberto Bertollini  7 , Laith J Abu-Raddad  1
Affiliations

Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections

Hiam Chemaitelly et al. J Travel Med. .

Abstract

Effectiveness of the 50-μg mRNA-1273.214 bivalent vaccine against SARS-CoV-2 infection was modest at 25% in a matched, retrospective, cohort study in Qatar comparing infection incidence in the bivalent cohort to that in the national no-recent-vaccination resident cohort. XBB* immune evasion, immune imprinting effects, or both, may explain findings.

Keywords: Hybrid immunity; Qatar; asymptomatic infection; natural infection; variant-containing COVID-19 vaccines; waning vaccine effectiveness.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Cumulative incidence of SARS-CoV-2 infection in the matched bivalent cohort and the no-recent-vaccination cohort. (B) mRNA-1273.214 bivalent vaccine effectiveness against SARS-CoV-2 infection overall and by documented prior infection status. Cohorts were matched exactly one-to-five by sex, 10-year age group, nationality, number of coexisting conditions and documented prior infection status to balance observed confounders between exposure groups.
See this image and copyright information in PMC

References

    1. Chalkias S, Harper C, Vrbicky K et al. A bivalent omicron-containing booster vaccine against COVID-19. N Engl J Med 2022; 387:1279–91. - PMC - PubMed
    1. Chemaitelly H, Ayoub HH, Tang P et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. Lancet Infect Dis 2023; 23:816–27. - PMC - PubMed
    1. Huiberts AJ, de Gier B, Hoeve CE et al. Effectiveness of bivalent mRNA booster vaccination against SARS-COV-2 omicron infection, the Netherlands, September to December 2022. Euro Surveill 2023; 28:pii=2300087. - PMC - PubMed
    1. Link-Gelles R, Ciesla AA, Fleming-Dutra KE et al. Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-COV-2 infection - increasing community access to testing program, United States, September-November 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1526–30. - PMC - PubMed
    1. Reynolds CJ, Pade C, Gibbons JM et al. Immune boosting by b.1.1.529 (omicron) depends on previous SARS-COV-2 exposure. Science 2022; 377:eabq1841. - PMC - PubMed

Publication types

Substances